• Publications
  • Influence
Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10.
A myocardial deficiency of CoQ10 is revealed, which is higher with increasing severity of disease and is reduced by therapy, and this biochemistry correlates with the effective treatment of cardiomyopathy with CoQ 10. Expand
Crystalline Vitamin B12.
Lovastatin decreases coenzyme Q levels in humans.
Data from the three protocols revealed that lovastatin does indeed lower levels of CoQ10, and this reduction would constitute a new risk of cardiac disease, since it is established that Co Q10 is indispensable for cardiac function. Expand
The identity of chemical and hormonal properties of the thyrotropin releasing hormone and pyroglutamyl-histidyl-proline amide.
This formulation of structure represents the elucidation of the first of the hypothalamic hormones that have been sought for so long and is chemically based on the chromatographic identity in seventeen diversified systems and biologically based on a quantitative comparison of the hormonal activities of the natural and synthetic products. Expand
Lovastatin decreases coenzyme Q levels in rats.
It is concluded that lovastatin does indeed lower tissue concentrations of CoQ and that a return to normal can be achieved by supplementation with CoQ. Expand
Evidence for a deficiency of coenzyme Q10 in human heart disease.
Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.
A long-term open-label study was begun in November 1982 with the goal of determining if tolerance of CoQ 10 and clinical improvement were maintained over long periods of time and it was thought it improper to use untreated control subjects in a long- term study. Expand
Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.
Preliminary CoQ10 withdrawal results showed severe clinical relapse with subsequent improvement onCoQ10 reinstatement, supporting the interpretation that treatment of these patients corrected a myocardial deficiency of CoQ 10 and increased contractility. Expand